AJCN Cancer Health Disparities Conference
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Ruiz-Narváez, E. A
Right arrow Articles by Campos, H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ruiz-Narváez, E. A
Right arrow Articles by Campos, H.
Agricola
Right arrow Articles by Ruiz-Narváez, E. A
Right arrow Articles by Campos, H.
American Journal of Clinical Nutrition, Vol. 87, No. 6, 1932-1938, June 2008
© 2008 American Society for Nutrition

ORIGINAL RESEARCH COMMUNICATION

Abdominal obesity and hyperglycemia mask the effect of a common APOC3 haplotype on the risk of myocardial infarction1,2,3

Edward A Ruiz-Narváez, Frank M Sacks and Hannia Campos

1 From the Department of Nutrition (EAR-N, FMS, and HC) and the Department of Epidemiology (EAR-N), Harvard School of Public Health, Boston, MA, and the Centro Centroamericano de Población, Universidad de Costa Rica, San Pedro, Costa Rica (HC)

Background: Plasma apolipoprotein (apo) C-III strongly predicts myocardial infarction (MI) and directly activates atherogenic processes in vascular cells. Genetic variation in the insulin response element of the APOC3 promoter is associated with an increased risk of MI.

Objective: The objective was to determine whether the APOC3 promoter variation affects plasma apo C-III concentrations and MI only when insulin sensitivity is normal.

Design: The APOC3*222 haplotype, defined by the minor alleles of the single nucleotide polymorphisms 3238C->G, –455T->C, and –482C->T, was studied in 1703 matched nonfatal case-control pairs with MI in the Central Valley of Costa Rica. We used fasting hyperglycemia and abdominal obesity as surrogates for insulin sensitivity.

Results: The APOC3*222 haplotype was associated with higher apo C-III concentrations only in those with the lowest waist circumference or fasting glucose concentration. The association between the APOC3*222 haplotype and nonfatal MI, previously reported in this population, was strongly influenced by fasting hyperglycemia and abdominal obesity. The odds ratios for MI for the APOC3*222 haplotype were 1.72 (95% CI: 1.16, 2.54) and 1.84 (1.31, 2.59) in subjects in the lowest quintiles of abdominal obesity and fasting hyperglycemia, respectively, and were 0.75 (0.54, 1.05) and 1.16 (0.85, 1.59) in subjects in the highest quintiles, respectively (P for interaction <0.05).

Conclusion: The results support the concept that mutations in the APOC3 promoter inhibit the down-regulation of APOC3 expression by insulin. This cardioprotective system becomes dysfunctional in abdominal obesity and hyperglycemia.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by The American Society for Nutrition